Search Results

You searched for : LatestNewsonRedHill

	RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material ... Jan 02
	RedHill's phase 2/3 COVID-19 study of opaganib passes second DSMB with unanimous recommendation to continue Opaganib potentially minimizes likelihood of resistance due to viral mutations by targeting a human cell component involved in viral replication ... Dec 22
	The RedHill Phase II / III candidate opaganib reduces ARDS-related blood clotting in the preclinical model in COVID-19 patients The results also show that opaganib inhibits SARS-CoV-2 virus replication and proinflammatory markers in relevant preclinical models ... Dec 17
	RedHill announces DSMB unanimous recommendation to continue COVID-19 opaganib phase 2/3 study The independent, pre-programmed DSMB unanimously recommends the continuation of the global Phase 2/3 study of orally administered opaganib in severe COVID-19 pneumonia... Nov 23
	RedHill Biopharma initiates phase 3 study of RHB-204 for first-line treatment of NTM disease RHB-204 is being evaluated as a first-line, stand-alone, oral treatment for pulmonary nontuberculous mycobacteria (NTM) disease ... Nov 21
	RedHill Biopharma collaborates with 2 pharma companies for manufacturing of COVID-19 vaccine Opaganib demonstrated potent antiviral activity against SARS-CoV-2, completely inhibiting viral replication in an in vitro model of human lung bronchial tissue. ... Oct 22
6 Matching result(s) found!

-Advertisements-

Trending Now
	Tackling Hypertension in South-East Asia: A Call to Action on World Hypertension DayMay 20, 2024
	FSSAI's Crackdown on Harmful Fruit Ripening Practices: Ensuring Public Health and ComplianceMay 20, 2024
	Uncovering the Presence of Microplastics in Human Blood and Their Health EffectsMay 18, 2024
	Potential Risks of Meftal: What Consumers and Doctors Should KnowMay 18, 2024
	Over-the-Counter Medications in India: A New Era of AccessibilityMay 18, 2024
	DCGI Acts Against Overcharging: New Regulations for Blood CentresMay 17, 2024
	Cattle as Hosts for Human and Bird Flu Viruses: A Potential Public Health ConcernMay 17, 2024
	The Ethics of Live Surgery Broadcasts: NMC Seeks Public OpinionMay 17, 2024
	Successful Removal of 3.7 KG Large Abdominal Tumor from 14-Year-Old Somalian Girl at KIMS Cuddles HospitalMay 16, 2024
	iLEAD Sets a Precedent by Launching a Graphic Anthology Authored by Multimedia, Animation and Graphics Students May 16, 2024
	Ramaiah Memorial Hospital Launches Novel Intra-Operative Radiation Therapy (IORT); Achieves significant advancement in Cancer Treatment to Enhance Quality of LifeMay 16, 2024
	IIITH Announces Product Management Summer SchoolMay 16, 2024
	Çelebi India's Delhi Cargo Terminal Successfully Handles Airbus H125 Helicopter ShipmentMay 16, 2024
	Plant-Based Diets and Prostate Cancer: New UCSF Study Shows Promising ResultsMay 16, 2024
	National Medical Commission Approves 112 New Medical CollegesMay 16, 2024
	Study Suggests That Chemotherapy Results in Physical Decline for Older Women with Breast CancerMay 16, 2024
	Google DeepMind's AlphaFold 3: Revolutionizing Drug Discovery with AIMay 16, 2024
	Hester Biosciences Ltd reports Consolidated Revenue growth of 18% at Rs. 79.3 crore, EBITDA up 37% to Rs. 16.4 crore and Net Profit up 12% to Rs. 6.40 crore in Q4FY24May 16, 2024
	Akshay Tritiya Parna Mahotsav heldMay 16, 2024
	IT Minister Sridhar Babu to grace the 10th National Facilities Managers Summit-2024, to be held in the cityMay 15, 2024

Search Results

RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib

RedHill's phase 2/3 COVID-19 study of opaganib passes second DSMB with unanimous recommendation to continue

The RedHill Phase II / III candidate opaganib reduces ARDS-related blood clotting in the preclinical model in COVID-19 patients

RedHill announces DSMB unanimous recommendation to continue COVID-19 opaganib phase 2/3 study

RedHill Biopharma initiates phase 3 study of RHB-204 for first-line treatment of NTM disease

RedHill Biopharma collaborates with 2 pharma companies for manufacturing of COVID-19 vaccine

Trending Now